Ouro Fino Saúde Animal Participações (OFSA3) investor relations material

Executive summary

• Achieved strong operational and financial performance in Q1 2026, with consolidated net revenue rising 32.1% year-over-year to R$250.5 million and significant margin expansion, driven by innovation, successful product launches, and robust execution across all business units.

• Adjusted EBITDA surged 139.0% to R$44.6 million, with margin expanding 7.9 p.p. to 17.8%.

• Adjusted net income reached R$20.8 million, up 902.7% year-over-year.

• Major corporate restructuring completed in October 2025, merging OF Agro into the parent company.

• Launched a new institutional brand campaign, reinforcing commitment to care and long-term value creation.

Financial highlights

• Net revenue: R$250.5 million (+32.1% vs. 1Q25); gross profit: R$134.9 million (+46.9% vs. 1Q25); gross margin: 53.9% (+5.4 p.p. vs. 1Q25).

• Adjusted EBITDA: R$44.6 million (+139.0% vs. 1Q25); adjusted EBITDA margin: 17.8% (+7.9 p.p. vs. 1Q25).

• Adjusted net income: R$20.8 million (+902.7% vs. 1Q25); adjusted net margin: 8.3% (+7.2 p.p. vs. 1Q25).

• Cash and cash equivalents at quarter-end were R$401.1 million, up from R$250.8 million at the end of 2025.

• Paid BRL 62 million in dividends on April 30, maintaining a strong payout while supporting investments.

Outlook and guidance

• Strategic plan through 2030 focuses on innovation, operational efficiency, disciplined capital allocation, and international expansion.

• Management expects continued growth in profitability and cash generation throughout 2026, with ongoing investments in R&D and commercial structures.

• No impacts from the 2025 Tax Reform reflected in Q1 2026 results; future effects will depend on further regulation.